

Special feature: Left Main Interventions

The SYNTAX score on its way out or ... towards artificial intelligence: part I



Patrick W. Serruys^{1*}, MD, PhD; Ply Chichareon^{2,3}, MD; Rodrigo Modolo^{2,4}, MD; David M. Leaman⁵, MD; Johan H.C. Reiber⁶, PhD; Håkan Emanuelsson⁷, MD; Carlo di Mario⁸, MD, PhD; Nico H.J. Pijls^{9,10}, MD, PhD; Marie-Angèle Morel¹¹, BSc; Marco Valgimigli¹², MD, PhD; Vasim Farooq¹³, MD, PhD; David van Klaveren¹⁴, PhD; Davide Capodanno¹⁵, MD, PhD; Daniele Andreini^{16,17}, MD, PhD; Christos V. Bourantas¹⁸, MD, PhD; Justin Davies¹, MD, PhD; Adrian P. Banning¹⁹, MD; Javier Escaned²⁰, MD, PhD; Jan J. Piek², MD, PhD; Mauro Echavarría-Pinto², MD, PhD; Charles A. Taylor²¹, PhD; Brian Thomsen²², MSc; Carlos Collet^{2,23}, MD; Giulio Pompilio^{16,17}, MD, PhD; Antonio L. Bartorelli^{16,24}, MD; Ben Glocker²⁵, PhD; Ovidiu Dressler²⁶, MD; Gregg W. Stone²⁷, MD; Yoshinobu Onuma²⁸, MD, PhD

The authors' affiliations can be found in the Appendix paragraph.

GUEST EDITOR: Alec Vahanian, MD, PhD; *Department of Cardiology, Hôpital Bichat-Claude Bernard, and University Paris VII, Paris, France*

Abbreviations

ACEF	age, creatinine, ejection fraction
CABG	coronary artery bypass grafting
CFD	computational flow dynamics
CFR	coronary flow reserve
CTO	chronic total occlusion
DAPT	dual antiplatelet therapy
ECG	electrocardiography
FFR	fractional flow reserve
FFR_{CT}	fractional flow reserve derived from computed tomography angiography
iFR	instantaneous wave-free ratio
MSCT	multislice computed tomography
NICE	National Institute for Health and Care Excellence
NOCA	non-obstructive coronary artery
PCI	percutaneous coronary intervention
QCA	quantitative coronary angiography
SYNTAX	SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery

Preamble

Recent publications on the SYNTAX (SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery) score have caught our attention and triggered a written reaction on the history and evolution of the SYNTAX score over the last decades. Among these publications, there is the editorial of Marie-Claude Morice, “Has the SYNTAX score become obsolete?”¹. The most recent guidelines on revascularisation also question the ability of the SYNTAX II score to predict four-year all-cause mortality ... even if the rate of mortality at four years in the EXCEL study was not yet available at the time of the writing of the guidelines...². A publication from Fuwai Hospital raises the following question, “Is the SYNTAX score II applicable in all percutaneous coronary intervention (PCI) patients?”³. Similarly, the team of the Thoraxcenter has published a paper in PLoS One entitled “SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease”⁴. A simplified anatomic scoring system designed by the Veterans Affairs based on the randomised population of the EXCEL trial is in preparation but needs to be

**Corresponding author: Cardiovascular Science Division of the NHLI within Imperial College of Science, Technology and Medicine, South Kensington Campus, London, SW7 2AZ, United Kingdom. E-mail: patrick.w.j.c.serruys@gmail.com*

validated before being publishable ... and the temptation to recalibrate the SYNTAX score II after completion of the EXCEL trial is appealing and may lure some of us.

All the past and future publications raise legitimate questions but conceptually run somewhat behind the facts or are misinterpreting the significance of the variety of scores derived from the original design of the anatomical SYNTAX score (Figure 1, Table 1)⁵⁻¹⁹.

The SYNTAX III Revolution trial has, for the first time, randomised two Heart Teams to use either the SYNTAX score II (anatomy plus comorbidities) derived from a conventional cineangiography or a SYNTAX score III (anatomy, plus functional significance, plus comorbidities) derived from a multislice computed tomography (MSCT), providing the Heart Team with a fractional flow reserve (FFR) for the assessment of the functional impact of the stenotic lesions¹⁸.

The next historic milestone will be the use of machine learning and artificial intelligence to provide the practitioner with a non-invasive, automatic, objective and reproducible analysis of the anatomic and functional SYNTAX score derived from MSCT, that will be automatically combined with the collected comorbidities of the patient in order to provide clinicians with a SYNTAX score III, a predictive assessment of late all-cause mortality, in case of either surgical or percutaneous treatment, based on anatomy,

Table 1. SYNTAX score and its variants.

1. Anatomic SYNTAX score (anatomic complexity)
Related to MACCE (all-cause mortality, stroke, myocardial infarction, revascularisation) prognosis from 1 to 5 years in the SYNTAX trial (PCI vs CABG in three-vessel disease and left main) ^{75,76} .
2. Logistic clinical SYNTAX score
Combination of anatomic complexity (anatomic SYNTAX score) and clinical comorbidities to predict all-cause mortality from 1 to 3 years in all-comers PCI trial ^{11,14-16} .
3. SYNTAX score II: anatomic complexity+comorbidities
Predict 4-year all-cause mortality in the SYNTAX trial ¹⁷ .
SYNTAX score II may be used as an inclusion criterion based on equipoise prediction of all-cause mortality after either PCI or surgery in three-vessel disease and left main ⁷⁷ .
4. SYNTAX score III: anatomic complexity+functionality (FFR/IFR)+comorbidities ¹⁸
5. SYNTAX III Revolution study
Treatment decision making between surgery and PCI in three-vessel disease and left main based solely on multislice CT scan with FFR _{CT} ¹⁸ .
CABG REVOLUTION study: planning and execution of surgery in three-vessel disease and left main applying SYNTAX score III derived solely from multislice CT scan with FFR _{CT} ⁷⁸ .




Figure 1. Evolution of the risk score algorithms derived from the historical SYNTAX I trial. ACEF: age, creatinine, ejection fraction; CABG: coronary artery bypass grafting; Compos: compositional; CrCl: creatinine clearance; CSS: clinical SYNTAX score; FSS: functional SYNTAX score; GRC: global risk classification; MI: myocardial infarction; MDRD: Modification of Diet in Renal Disease; SrCr: serum creatinine; SYNTAX: SYnergy between PCI with TAXus and Cardiac Surgery. Adapted with permission from Capodanno⁵ and Modolo et al¹².

comorbidities and functionality. However, before describing these future options, let us review the historical foundation, the evolution and perpetuation of the score over the last decades.

THE ROLE OF SCORES IN THE FIELD OF INTERVENTIONAL CARDIOLOGY

A risk score combines multiple predictors to forecast objectively the probability of specific outcomes such as procedural complications, morbidities or mortality that may affect individual patients in the short or long term²⁰. Many risk scores have been developed to serve various purposes within the field of cardiology²⁰. The anatomic SYNTAX score was initially developed as an objective tool to assess the complexity of coronary artery disease (CAD) in the context of a randomised trial comparing PCI and coronary artery bypass grafting (CABG). Subsequently, other scores (such as the logistic clinical SYNTAX score, the age, creatinine, ejection fraction [ACEF] score and a novel risk score) started to target specifically the short-term and long-term prognosis of PCI treatment^{14,21}. Alternatively, the PRECISE-DAPT score, the PARIS risk score and the dual antiplatelet therapy (DAPT) score have attempted to predict bleeding, thereby providing guidance on antiplatelet strategies after PCI²²⁻²⁴.

The SYNTAX score II, which combined the anatomic SYNTAX score and clinical predictors, was developed to predict four-year all-cause mortality and on this basis to advise the best and safest revascularisation strategy (PCI versus CABG) in patients with multivessel disease with or without a left main stenotic lesion¹⁷.

Another aspect of the clinical impact of the risk score is related to clinical trials: for example, in the historical development of transcatheter aortic valve replacement (TAVR), the Society of Thoracic Surgeons risk score was used to classify patients into low, intermediate and high risk²⁵. The score was then used to assess various levels of risk and helped to conduct trials with progressively decreasing risk: from non-operable to high-, intermediate- and low-risk patients²⁶⁻²⁸. Another purpose of the score is its ability to characterise the level of objective risk that patients endured when treated by specific operators and hospitals. In that respect, the use of risk scores allows appropriate adjustment of treatment failure or success in the most difficult patients treated in a particular hospital.

Before integration into practice, the predictive performance of risk scores needs to be tested in a population different from the one in which the score was developed (external validation). Ultimately, the value of risk scores needs to be tested in a randomised trial to assess their predictive performance in outcomes and patient care.

Furthermore, the score itself is not static. There are changes in the risk profiles of the patients, such as advanced age, higher prevalence of diabetes, etc. Moreover, there is also change in technology, and risk scores have to be adjusted and adapted continuously with the identification of new predictors with additional prognostic value. Furthermore, the predictive performances of scores can be dissimilar from their derivation cohort due to differences in the level of care such as primary versus secondary or tertiary, or related to the




Figure 2. Measurement of reactive hyperaemia in bypass graft. Radiopaque epicardial marker pairs were implanted during surgery in the newly revascularised regions near the coronary anastomosis to assess regional wall systolic and diastolic motion (top). Bypass flow and reactive hyperaemia were measured using magnetic flow after transient occlusion of the bypass graft (middle). Maximal diastolic graft flow recorded immediately after reperfusion (Qd_{max}) and baseline diastolic graft flow (Qd) were measured to calculate percentage of reactive hyperaemia. The reactive hyperaemia histogram shows a non-Gaussian distribution with almost 40% of grafts showing no reactive hyperaemia (bottom). Adapted from Serruys et al³³ and Brower et al³², with permission.

geographic areas in which the scores are applied²⁹. Therefore, scores should be revised or updated on a regular basis as soon as they show a loss of predictive value (e.g., discrimination and calibration).

(PRE) HISTORICAL FOUNDATION OF THE SYNTAX SCORES: THE LEAMAN SCORE

In 1976, when Patrick W. Serruys arrived at the Thoraxcenter, he was immediately assigned to a surgical research project: measurement of reactive hyperaemia in bypass grafts combined with regional wall motion assessed from biplane cine-filming of the systolic/diastolic motion of epicardial radiopaque markers implanted at the time of surgery, distally to the site of the graft anastomosis (**Figure 2**)^{30,31}. In brief, at the end of surgical bypass grafting and when the patient was no longer on cardiopulmonary bypass, the surgeon clamped transiently the saphenous graft or the left internal mammary artery, and the reactive hyperaemia following the transient occlusion was measured with a magnetic flow meter fitted around the graft. The major finding was that in 40% of the cases graft occlusion was not followed by reactive hyperaemia, in other words it was conceivable that 40% of the stenotic native vessels were not flow-limiting (**Figure 2**)^{32,33}. The only non-surgeon author (P.W. Serruys) of the publication was then introduced and “initiated” to the field of reactive hyperaemia and segmental blood supply to the human left ventricle.

A few years later, a similar attempt to measure reactive hyperaemia was reported in the clinical setting of PCI, with the use of

a Grüntzig balloon instrumented at its tip with a Doppler emitter/receiver device allowing the measurement of reactive hyperaemia after balloon deflation (**Figure 3**)³⁴.

In those days, reactive or pharmacological hyperaemia as a marker of flow-limiting stenosis became part of the “physiological” background and mindset of P.W. Serruys. For the rest of his career, hyperaemia (and coronary flow reserve), flow-limiting anatomy³⁵, microvascular resistance (pressure flow loop and hyperaemic index)^{36,37}, and pressure gradient across stenosis (stenotic flow reserve [SFR])³⁸ became obsessional topics of research³⁸⁻⁴⁰.

In 1979, a senior American cardiologist, David Leaman, joined the Thoraxcenter for a sabbatical year during which he worked with the team of the Thoraxcenter on the long-term follow-up of CABG, a project subsidised by the Interuniversity Cardiology Institute of the Netherlands (ICIN). For that project, D. Leaman and P.W. Serruys reviewed the existing literature on blood supply to the left ventricle by regional (segmental) coronary circulation and came up with a weighted assessment of the relative and absolute supply of blood to the human left ventricle by each main branch and side branch of the coronary tree (**Figure 4**)⁴¹.

For an understanding of the anatomic SYNTAX score, it is essential to keep that concept in mind; it is essential groundwork that cannot be destabilised by another weight calibration derived, for instance, from the therapeutic impact of a revascularisation approach as investigated in CABG/PCI trials. Indeed, it has been argued that the Leaman score (or the anatomic SYNTAX




Figure 3. Reactive hyperaemia measurement of the coronary artery stenosis during percutaneous transluminal coronary angioplasty as a guide for functional assessment. A) Schematic cross-sectional drawing of Doppler tip angioplasty catheter with inflated balloon in an artery. B) Doppler shift (kHz, mean±standard error) during four sequential dilations. C) Examples of mean and phasic Doppler signals before, during and after balloon inflation. Reactive hyperaemia occurs after balloon deflation. C1) First transluminal occlusion using a balloon inflation pressure of 6 atmospheres (atm). C2) Second transluminal occlusion using a balloon inflation pressure of 8 atm. C3) Third transluminal occlusion using a balloon inflation pressure of 10 atm. C4) Fourth transluminal occlusion using a balloon inflation pressure of 12 atm. Va: resting velocity after dilatation; Vb; resting velocity before dilatation; Vh: peak reactive hyperaemia. Reprinted from Serruys et al³⁴, with permission.




Figure 4. The Leaman score; weighted assessment of the relative and absolute supply of blood to the human left ventricle by each main branch and side branch of the coronary tree. Coronary artery segments and the weighting factor assigned to each segment in the right-dominant and left-dominant coronary artery system. Also, the percent luminal diameter reduction of the coronary artery segment and the weighting factor assigned to the specific percentage reductions. AC: atrial circumflex; AM: acute marginal branches; AV: atrioventricular nodal branch; LAD: left anterior descending; LCA: left coronary artery; OM: obtuse marginal; PD: posterior descending branch; PL: posterolateral branch; RPD: right posterior descending; SN: sinus node branch; V: ventricular branch. Reprinted from Leaman et al⁴¹, with permission.

score) for the left main trunk was “overestimated”, considering the current good PCI prognosis of left main treatment. The opinion related to therapeutic results of trials comparing PCI with CABG is a “disruptive interaction” on an otherwise sound physiologic concept: closure of the left main is almost inevitably associated with a deadly consequence, but fortunately stenting of the left main seldom results in fatal outcome. However, it does not invalidate the intrinsic physiological weight of the left main as a major source of blood supply. One criticism so far not reported is the excessive weight given to the presence of occlusion compared with non-occlusive stenosis. With the progress of chronic total occlusion (CTO) recanalisation and more than 90% success in selected centres, this can possibly be considered overweighted.

By the way, more than 24 years after its creation, the Leaman score was reintroduced in the era of non-invasive CT angiography: a seven-year follow-up of 1,196 patients investigated to rule out obstructive CAD by MSCT showed that the worst prognosis was observed in patients with obstructive or non-obstructive coronary artery (NOCA) lesions and a high Leaman score, which, indeed, reflects the diffuse and extensive character of the disease (Figure 5)⁴².

1979: Pd/Pa ERUPTED INTO OUR CLINICAL WORLD

In the same year (1979) and following the attendance of the second course of Andreas Grüntzig in Zurich, Marcel van den Brand (Marcel van den Brand deceased in 2018) and P.W. Serruys purchased five Grüntzig DG balloons (one 4.2 Fr, two 3.7 Fr and two 3.5 Fr) on behalf of the Thoraxcenter.

Younger generations of interventional cardiologists are probably unaware that coronary angiography during the angioplasty procedure was barely feasible (except that very diluted contrast medium and high injection pressure were used) as soon as the bulky Grüntzig balloon had been inserted in the shaft of the guiding catheter in spite of its large calibre (9.5 Fr O.D.). Therefore, the entire procedure was guided by watching, not the fluoroscopic screen, but two pressure curves on the haemodynamic monitoring screen. Indeed, the central lumen of the Grüntzig balloon allowed the measurement of the pressure at the tip of the balloon catheter (John Simpson had not yet invented the steerable movable guidewire).

In advancing the balloon in the coronaries, we knew that we had crossed the stenotic lesion when Pd/Pa suddenly decreased.




Figure 5. Kaplan-Meier survival curves for hard cardiac events stratified by CAD severity (obstructive versus non-obstructive) and coronary atherosclerotic burden (CT-LeSc >5 vs ≤5). The event-free survival for the patients with non-obstructive CAD and a high (>5) CT-LeSc (78.6%) was similar to that for patients with obstructive CAD and a high CT-LeSc (76.5%; log-rank, $p=0.63$) and was even numerically lower than that for patients with obstructive CAD and a low CT-LeSc (80.7%; log-rank, $p=0.810$). CAD: coronary artery disease; CT-LeSc: CT-adapted Leaman score. Reprinted from Mushtaq et al⁴², with permission.

In a few cases, Pd/Pa further decreased when the balloon was inflated (recording then a wedge pressure), while, after deflation, Pd/Pa gradient had to disappear immediately and the two pressure curves eventually had to become superimposed ... (Figure 6)⁴³. If the pressure curves (Pd/Pa) after balloon deflation remained separated, it was time to call the surgeon...

It was a vivid, life or death “introduction” to the field of Pd/Pa, that would keep us intellectually busy for the four decades to come.

As early as 1985, William Wijns (then in interventional cardiology training at the Thoraxcenter) and P.W. Serruys reported on Pd/Pa, minimal lumen area by quantitative coronary angiography (QCA)⁴⁴, ST-T changes and thallium scintigraphy during maximal exercise in an era preceding the invention of the velocity and pressure wire. Some of the published figures in *Circulation* still look very contemporary and would today mislead many young fellows on the historical date of their creation (Figure 7)⁴⁵.

When the paper was flatly rejected by *Circulation*, the first two authors (W. Wijns and P.W. Serruys) shipped to the journal in small containers all the pressure tracings, all the contour detections of the QCA and all the exercise thallium scintigraphies quantified by, at that time, a brand-new software by Hans Reiber, a brilliant engineer of the bioengineering group at the Thoraxcenter. As a testimony to that shipping, the reader may find in the 1985 publication a footnote informing the readership that they could obtain from the publisher of *Circulation* – for the modest sum of three

dollars – microfilms of all the data reported in the paper... an early version of the “big data and data sharing” era⁴⁵.

P.W. Serruys believes that, when the group of Eindhoven and Aalst performed their spectacular validation of the FFR concept versus exercise testing, dobutamine stress, and thallium scintigraphy, published in the *New England Journal of Medicine*⁴⁶, this probably took W. Wijns’ mind back to that seminal observation made at the Thoraxcenter almost one decade earlier.

Following the publication of W. Wijns and P.W. Serruys and as early as 1988, Poiseuille and Bernoulli resistance values derived from QCA as well as the graphical representation of the Lance Gould equation³⁵, pre and post percutaneous transluminal coronary angioplasty, were available on line in the catheterisation laboratory of the Thoraxcenter and reported in the literature (Figure 8)⁴⁷. These technical assessments came too early in the history of interventional cardiology, were not disseminated and adopted by the emerging community of interventional cardiologists and were only appreciated by a very small minority of pioneers.

FROM YOUNG’S EQUATION TO ANGIOGRAPHICALLY DERIVED FFR

Let us open another parenthesis and illustrate by a cartoon how physiology made its professional entry into percutaneous intervention. When P.W. Serruys left the ranks of the university the master equation for determining a gradient across a stenosis was the Young equation $[\frac{\Delta p}{\rho U^2} = \frac{K_\theta}{Re} + \frac{K_s}{2} (\frac{A_0}{A_1} - 1)^2]$ which was simplified as




Figure 6. Intracoronary pressure changing during percutaneous transluminal coronary angioplasty. Documentation of pressures during the world's first coronary angioplasty on 16 September 1977 at the University Hospital of Zurich in Switzerland. The top curve represents the aortic pressure at the tip of the guiding catheter in the coronary cusp (AoP). The bottom curve represents the pressure at the tip of the balloon catheter while in the coronary artery (CoP, damped because of the tiny lumen transmitting the pressure). During advancement of the deflated balloon into the diseased vessel, the distal pressure dropped when the tip of the deflated balloon crossed the stenotic lesion; during the inflation of the balloon the distal pressure further decreased (wedge pressure); at the time of the deflation and in the absence of residual stenosis the tracing of the distal pressure rejoined the curve of the central pressure. This testifies to a good haemodynamic result of angioplasty. Reprinted from Meier B⁴³, with permission from Europa Digital & Publishing.




Figure 7. The relationship between pressure gradient across a stenotic lesion, area stenosis and results of thallium scintigraphy during maximal exercise. The relationship between the mean pressure gradient normalised for the mean aortic pressure and the residual obstruction area (in mm²) (after subtraction of the area of the angioplasty catheter) is non-linear; the best fit is obtained by a logarithmic function ($r=0.74$) (left panel). The relationships among mean normalised pressure gradient, percentage area stenosis, and the results of thallium scintigraphy are shown in the right panel. Open circles represent patients with normal scintigrams (group I, $n=25$), half-filled circles represent patients with abnormal thallium but normal exercise tests (group II, $n=7$) and filled circles represent patients with both abnormal thallium and exercise tests (group III, $n=10$). Reprinted from Wijns et al⁴⁵, with permission.




Figure 8. Final result of the analysis of the coronary segment by quantitative coronary angiography. The screenshot (dated 12.01.1989) on the left-hand side shows the automatically detected luminal contours, the interpolated reference diameter, and the diameter function. The screenshot on the right-hand side shows on the vertical axis Pd/Pa dropping with the increase of hyperaemic flow up to the point where the post-stenotic driving pressure becomes the limiting factor in the further increase of the hyperaemic flow (cross point on the diagram depicting the line reflecting the linear relationship between pressure and maximal hyperaemic flow). The stenotic flow reserve (SFR), the Poiseuille resistance, the turbulence resistance and the flow reserve were displayed on the screen, online in the lab. CF: calibration factor; % D; percentage diameter stenosis; D1: minimal lumen diameter; D2: reference lumen diameter; Delta P. (mmHg): difference of pressure between Pa (aortic pressure) and Pd (distal coronary pressure); FR: flow reserve; % A: percentage area stenosis; SFR: stenotic flow reserve

follows: $[\Delta P = FV + SV^2 + D \frac{V}{V_r} - 1)V^2]$ and popularised by L. Gould³⁵ and R.L. Kirkeeide⁴⁹. In brief, friction of laminar layers of flow at the entry and inside the stenosis and separation of the laminar layers with loss of kinetic energy at the exit of the stenosis (swirling, flow reversal, etc.) were the two major haemodynamic generators of the pressure gradient. Scientists always rediscover the laws of the universe... Daniel Bernoulli (1700-1782) and Jean Léonard Marie Poiseuille (1799-1869) were the Swiss and French physicists who described these principles in the eighteenth and nineteenth century, respectively. For the interventional cardiologists, the excitement mounted with the creation of the velocity wire, that allowed us to measure the coronary flow velocity and the coronary flow reserve. A series of trials using the flow velocity wire and the assessment of coronary flow reserve (DEBATE I, II, DESTINI) were conducted to prove or dismiss the value of provisional balloon angioplasty versus upfront and definitive stenting^{39,40}.

In these trials, the guidance of the procedure relied on the sequential improvement of diameter stenosis assessed by QCA, combined with increase in coronary flow reserve (2.5 threshold) assessed with velocity wire. These trials helped us to demonstrate that upfront and systematic stenting was superior to provisional balloon angioplasty. Three years later (1991), the pressure wire was manufactured in Sweden by Radi Medical Systems and became a powerful tool of research before becoming a clinical device. During his sabbatical time at the Thoraxcenter, Håkan Emanuelsson carried out the first clinical evaluation of the new device⁵⁰.

For the team at the Thoraxcenter (Carlo di Mario and Javier Escaned were part of the team), combining left ventricular pressure, its first derivative, intracoronary pressure and velocity parameter became an intense topic of clinical investigation and research (**Figure 9-Figure 11**)⁵¹, whereas Nico Pijls used the pressure device as an investigational tool initially to study the collateral circulation in dogs⁵². Later, together with Bernard de Bruyne and W. Wijns, they formulated the concept of FFR and beautifully validated it as a diagnostic clinical tool, non-inferior to exercise testing, dobutamine stress echocardiography, and thallium scintigraphy. Today these three diagnostic modalities are disregarded as non-specific or non-sensitive! The above-mentioned trials with coronary flow reserve (CFR) and diameter stenosis (DEBATE I, II) were historically posterior to the creation of the FFR concept in 1996 (**Figure 9**), but for the pioneers of FFR numerous years of hard work were needed to demonstrate the good prognostic value of treatment deferral when the stenosis was physiologically non-significant (DEFER⁵³, FAME I⁵⁴ and FAME II studies⁵⁵).

With the advent of FFR, the classic 2D QCA was progressively discredited, if not ridiculed. To be honest, P.W. Serruys did not pay too much attention to this denigrating process since his clinical work was dedicated to the promotion of the emerging stent technology following the clinical success of the BENESTENT trial in 1994⁵⁶. Today, it is somewhat ironic to see a colour-coded, pseudo 3D QCA (an elliptical surface derived from two diameters not even orthogonal), with quantitative flow ratio being embraced as a good surrogate for the pressure-derived




Figure 9. A helicopter view of the field of coronary physiology, its development and ramifications. Adapted from Echavarría-Pinto et al¹. With permission from Europa Digital & Publishing.




Figure 10. Pressure-velocity analysis and haemodynamic parameters (the 1993 approach). *A*) From top to bottom: electrocardiogram (ecg), proximal coronary pressure (prox.cor.press) recorded through the guiding catheter (mmHg), distal coronary pressure (dist.cor.press) recorded with a tip-mounted pressure guidewire (mmHg), coronary flow velocity recorded with a Doppler guidewire (cm/s), and instantaneous transstenotic pressure gradient (mmHg) recorded with a pressure wire. Note that the systolic/diastolic changes in flow velocity correspond to the phasic variations of the transstenotic gradient, with the maximal velocity and gradient in proto-mid-diastole. *B*) Upper panel from top to bottom: electrocardiogram (ecg), aortic pressure (Ao.press; tip manometry), left ventricular pressure (LV.press; tip manometry), coronary blood flow velocity (Doppler guidewire), and first derivative of the left ventricular pressure (dP/dt). The dotted areas indicate the intervals (a precursor of the instantaneous wave-free ratio) used for the analysis of the pressure/flow velocity relation from the digitised pressure and flow velocity (starting point, 20 msec after peak negative dP/dt, endpoint: left ventricular end-diastolic pressure/upstroke of the positive left ventricular dP/dt). Lower panel: velocity/pressure loops of three consecutive cardiac cycles superimposed (clockwise rotation) in baseline conditions and at the peak effect of papaverine. The regression lines (IHDVPS – index of hyperaemic diastolic velocity pressure slope) calculated in the mid-late diastolic phases are displayed and extrapolated up to the zero-flow pressure (Pzf). *C*) Equations to calculate fractional flow reserve (FFR), coronary flow reserve (CFR), stenotic resistance (SR) and microvascular resistance (MR). Adapted from Serruys et al³⁶, with permission.

FFR by pioneers such as W. Wijns, B. de Bruyne, William Fearon and others... (including P.W. Serruys, who fully endorsed their enthusiasm for that methodological approach)^{18,57,58}; besides, the Erasmus University in collaboration with the University of Ioannina was among the first to validate the so-called virtual FFR – FFR estimated from 3D QCA using computational flow dynamic techniques versus the real pressure-derived FFR⁵⁹. The value of computational flow dynamics (CFD)-derived FFR in the clinical arena is apparent especially in China, India... and the rest of the world which needs a software tool such as angiographically derived FFR, that is less expensive than the pressure wire hardware to justify physiologically PCI treatment in their overpopulated countries.

On the other hand, the anatomic SYNTAX score did benefit from the introduction of physiology in interventional cardiology.

The functional SYNTAX score was generated by the “physiologist” interventional cardiologist and became a “must” in the evaluation of three-vessel disease: only flow-limiting stenosis had to be taken into account in the SYNTAX score calculation (**Figure 1**)¹².

In 2010, the FFR pioneers were intellectually destabilised by the introduction of instantaneous wave-free ratio (iFR) originating from the lab of Justin Davies⁶⁰. Large outcome trials (the DEFINE-FLAIR⁶¹ and iFR-SWEDEHEART studies⁶²) trivialised the fierce debate that was progressively evolving at that time between the proponents of iFR and FFR.

In the meantime, but a decade before, another equation (the Navier-Stokes equation) made its entry into the field of cardiology with the use of finite element and shear stress computation and simulation⁶³. The Navier-Stokes equations describe the fluid movement in 3D space based on the law of conservation of energy




Figure 11. Relation between coronary flow and pressure and coronary haemodynamic patterns in resting and hyperaemic conditions. Left panel shows the illustration from Serruys et al in the *American Journal of Cardiology* 1993³⁶. Upper part, flow/pressure relation in resting and hyperaemic conditions according to the description of Klocke⁷³. Three confounding factors may obscure the interpretation of the change in coronary flow reserve following a percutaneous transluminal coronary angioplasty procedure: (1) an increase in resting blood flow; (2) acute or chronic changes in the flow/pressure relation during hyperaemia; (3) alteration of the severity of the stenotic lesion treated by balloon angioplasty. Lower part, from top to bottom, an example of normal epicardial artery with normal distal vascular response and of a significant epicardial stenosis inducing a pressure gradient in baseline and hyperaemic conditions and an impaired coronary flow reserve. The presence of an abnormal distal vascular response (last two series of diagrams) minimises the changes in the transstenotic pressure gradient and in maximal flow observed with and without an epicardial stenosis. Right panel shows the schematic representation of the coronary haemodynamic patterns documented 20 years later by Echavarría-Pinto et al⁶⁹. A) Vessel with concordantly abnormal FFR and CFR and normal (low) index of microcirculatory resistance (IMR). B) Vessel with a non-severe focal stenosis without associated diffuse atherosclerotic narrowing (DAN) or microcirculatory dysfunction (MCD). C) Vessel with a focal stenosis and DAN. Despite a normal FFR, an abnormal CFR with low IMR suggests that diffuse epicardial atherosclerosis is the predominantly affected compartment. D) Stenosis with normal FFR and abnormal CFR. At difference with the case shown in C, the presence of MCD, and not DAN, may account for the discrepancy between FFR and CFR. E) Vessel with a stenosis that, despite showing an abnormal FFR, has preserved CFR as a result of well-preserved microcirculation and absence of significant DAN. Reprinted from Serruys et al³⁶ and Echavarría-Pinto et al⁶⁹, with permission.

and mass. By solving the Navier-Stokes equations, the fluid velocities at certain locations can be obtained⁶⁴. Pressure gradient across an anatomic stenosis was derived using computational fluid dynamic techniques and, thanks to the fundamental work of Charles Taylor, FFR derived from computed tomography angiography (FFR_{CT}) was derived from MSCT and colour coded along the coronary lumen delineated by the MSCT⁶⁵.

The colour-coded 3D MSCT image inspired the companies that used to quantify 2D contours on coronary cineangiograms. Two

angiographic views separated by more than 25-degree projection were considered as theoretically sufficient to create a pseudo 3D angiogram. To apply to this 3D lumen the simple equation of Gould (pseudo CFD)^{59,66} or the complex Navier-Stokes equation (true CFD)⁶⁷ was then a technical “piece of cake”. From then on, everybody could have their own angiographically derived FFR or FFR_{CT} without instrumenting the coronary artery with a pressure wire, and the functional SYNTAX score became a firmly established entity. In 2017, the National Institute for Health and Care Excellence

(NICE) recommended FFR_{CT} in their clinical pathway for the assessment and diagnosis of patients with suspected stable angina⁶⁸.

Over the years, many investigators (e.g., Jan J. Piek, J. Escaned, Mauro Echavarría-Pinto) have emphasised the need to combine FFR and CFR (as we did originally) to elucidate fully whether ischaemia is related to the altered conductance of the major epicardial vessel or the altered resistance of the microvasculature or both (Figure 11). Multiple areas of concordance, discordance, positive and negative mismatch between FFR and CFR have been clearly identified by these authors (Figure 12)⁶⁹.

Today, without pressure/velocity hardware, they (e.g., J. Piek, J. Escaned, M. Echavarría-Pinto...and others) could easily resolve their intellectual dilemma and have, through a single coronary injection of angiographic contrast medium, the simultaneous acquisition of both angiographically derived FFR and CFR. We would not be surprised to see the so-called “Vogel’s technique” being resurrected. This digital angiographic technique was introduced by Vogel et al in 1984 to measure CFR using the myocardial contrast appearance time from a simple electrocardiography-triggered coronary angiogram⁷⁰. The method quantified the time of the contrast medium appearance in the major epicardial vessel divided by the change in density of the contrast medium in the myocardium at baseline and maximal hyperaemia. Therefore, the operator could evaluate, online in the lab, the CFR derived from conventional angiography⁷¹ (Figure 9, bottom right). The question is ... who in the industry will close the loop and jump back to

this technical opportunity, “Vogel’s technique”, that used to be an online software in the cine-fluoroscopic system of Philips⁷¹?

Appendix. Authors’ affiliations

1. NHLI, Imperial College London, London, United Kingdom;
2. Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands;
3. Cardiology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand;
4. Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, Brazil;
5. Milton Hershey Medical Center, Penn State Heart and Vascular Institute, Hershey, PA, USA;
6. Department of Radiology, Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands;
7. Astra Charwood Clinical R & D, Loughborough, United Kingdom;
8. Division of Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy;
9. Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands;
10. Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands;
11. Cardialysis BV, Rotterdam, the Netherlands;
12. Department of Cardiology, Bern University Hospital, Bern, Switzerland;
13. University Hospital of Wales, Cardiff, United Kingdom;
14. Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands;
15. Division of Cardiology, Cardio-Thoracic-Vascular Department, Azienda




Figure 12. Combined use of intracoronary pressure and flow to assess ischaemic heart disease. Left panel shows the conceptual plot of the coronary flow reserve (CFR) and fractional flow reserve (FFR) relationship showing the four different quadrants. Right panel shows the scatter plot of FFR and CFR relationship across 467 vessels (299 investigated with Doppler-derived flow and 168 with thermodilution-derived flow) with intermediate stenosis evaluated with pressure and flow sensors, at Hospital Clinico San Carlos, Madrid, Spain, and Academic Medical Center-University of Amsterdam, Amsterdam, the Netherlands. Vessels in blue and red were concordantly abnormal ($CFR < 2$ and $FFR \leq 0.80$) and concordantly normal ($CFR \geq 2$ and $FFR > 0.80$), respectively. Vessels in orange exhibited $CFR \geq 2$ and $FFR < 0.80$, suggestive of predominantly focal disease. The yellow region contains vessels with $CFR < 2$ and $FFR > 0.80$ suggestive of predominantly diffuse epicardial or microcirculatory disease. Finally, within this region, vessels in grey exhibited only a minor hyperaemic pressure drop (< 5 mmHg) suggestive of predominant microcirculatory disease. Adapted from Echavarría-Pinto et al⁷⁴, with permission.

Ospedaliero Universitaria “Policlinico-Vittorio Emanuele”, Catania, Italy; 16. Centro Cardiologico Monzino, IRCCS, Milan, Italy; 17. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 18. Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom; 19. Oxford Heart Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; 20. Department of Cardiology, Hospital Clinico San Carlos, Madrid, Spain; 21. HeartFlow, Redwood City, CA, USA; 22. GE Healthcare, Waukesha, WI, USA; 23. Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; 24. Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, Milan, Italy; 25. Biomedical Image Analysis Group, Department of Computing, Imperial College London, London, United Kingdom; 26. Cardiovascular Research Foundation, New York, NY, USA; 27. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York and the Cardiovascular Research Foundation, New York, NY, USA; 28. Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands

Guest Editor

This paper was guest edited by Alec Vahanian, MD, PhD; Department of Cardiology, Hôpital Bichat-Claude Bernard, and University Paris VII, Paris, France.

Acknowledgements

We wish to acknowledge all those who contributed to the SYNTAX score.

Conflict of interest statement

P.W. Serruys reports personal fees from Abbott Laboratories, AstraZeneca, Biotronik, Cardialysis, GLG Research, Medtronic, Sino Medical Sciences Technology, Société Europa Digital & Publishing, Stentys France, Svelte Medical Systems, Philips/Volcano, St. Jude Medical, Qualimed, and Xeltis, outside the submitted work. P. Chichareon reports a research grant from Biosensors outside the submitted work. R. Modolo has received research grants from Biosensors outside the submitted work and from the Sao Paulo Research Foundation (FAPESP - grant number 2017/22013-8). N. Pijls has received institutional research grants from Abbott, Hexacath and HeartFlow, is a consultant for Abbott, Opsens, and GE Healthcare, and possesses equity in Philips, HeartFlow, and ASML. M. Valgimigli reports grants and personal fees from Abbott, Terumo and AstraZeneca, personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen, Idorsia, Alvimedica, Biosensors, CoreFlow, Vifor and Bristol-Myers Squibb, and grants from Medicure, outside the submitted work. J. Davies reports grants, personal fees and other from Philips Volcano, outside the submitted work; in addition, J. Davies has a patent iFR with royalties paid by Philips Volcano to Imperial College London. A. Banning is partially supported by the NIHR Oxford Biomedical Research Centre and reports grants from Boston Scientific and personal fees from Boston Scientific, Medtronic and

Abbott Vascular, during the conduct of the study. J.J. Piek reports non-financial support from Abbott Vascular and personal fees and non-financial support from Philips/Volcano, outside the submitted work. B. Thomsen is an employee of GE Healthcare. B. Glocker reports grants from HeartFlow and the European Commission, during the conduct of the study, personal fees from Kheiron Medical Technologies, Definiens, Axon Advisors and GlaxoSmithKline, grants from UKRI, EPSRC, Innovate UK, and MRC/NIHR, outside the submitted work. C. Collet reports grants and personal fees from HeartFlow Inc, and personal fees from Philips and Abbott Vascular, outside the submitted work. G.W. Stone reports personal fees from Terumo, Amaranth, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Matrizyme, Miracor, Neovasc, V-wave, Abiomed, Claret, Backbeat, Sirtex and MAIA Pharmaceuticals, personal fees and other from Ancora, Qool Therapeutics and SpectraWave, other from Cagent, Applied Therapeutics, Biostar family of funds and MedFocus family of funds, outside the submitted work; Columbia University, his employer, receives royalties from Abbott for sales of the MitraClip. Y. Onuma reports being a member of the advisory board of Abbott Vascular. C. Taylor reports being a shareholder in and an employee of HeartFlow. The other authors have no conflicts of interest to declare. The Guest Editor is a consultant for Edwards Lifesciences.

References

- Morice MC. Has the SYNTAX Score Become Obsolete? *J Am Coll Cardiol*. 2018;72:1330-1.
- Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2019;40:87-165.
- Gao G, Zhao Y, Zhang D, He Y, Song C, Zhu C, Guan C, Xu B, Yin D, Dou K. Is the SYNTAX Score II applicable in all percutaneous coronary intervention patients? *Catheter Cardiovasc Interv*. 2019;93:779-86.
- Vroegindewey MM, Schuurman AS, Oemrawsingh RM, van Geuns RJ, Kardys I, Ligthart J, Daemen J, Boersma E, Serruys PW, Akkerhuis KM. SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease. *PLoS One*. 2018;13:e0200076.
- Capodanno D. Lost in calculation: the clinical SYNTAX score goes logistic. *Eur Heart J*. 2012;33:3008-10.
- Généreux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, Xu K, Parise H, Mehran R, Serruys PW, Stone GW. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score. *J Am Coll Cardiol*. 2012;59:2165-74.
- Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. *Circulation*. 2013;128:141-51.
- Farooq V, Girasis C, Magro M, Onuma Y, Morel MA, Heo JH, Garcia-Garcia H, Kappetein AP, van den Brand M, Holmes DR, Mack M, Feldman T,

- Colombo A, Stähle E, James S, Carrie D, Fournial G, van Es GA, Dawkins KD, Mohr FW, Morice MC, Serruys PW. The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. *EuroIntervention*. 2013;8:1277-85.
9. Brugaletta S, Magro M, Simsek C, Heo JH, de Boer S, Ligthart J, Witberg K, Farooq V, van Geuns RJ, Schultz C, van Mieghem N, Regar E, Zijlstra F, Duckers HJ, de Jaegere P, Muller JE, van der Steen AF, Boersma E, Garcia-Garcia HM, Serruys PW. Plaque compositional Syntax score: combining angiography and lipid burden in coronary artery disease. *JACC Cardiovasc Imaging*. 2012;5:S119-21.
10. Magro M, Nauta S, Simsek C, Onuma Y, Garg S, van der Heide E, van der Giessen WJ, Boersma E, van Domburg RT, van Geuns RJ, Serruys PW. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: The MI SYNTAXscore study. *Am Heart J*. 2011;161:771-81.
11. Garg S, Sarno G, Garcia-Garcia HM, Girasis C, Wykrzykowska J, Dawkins KD, Serruys PW; ARTS-II Investigators. A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score. *Circ Cardiovasc Interv*. 2010;3:317-26.
12. Nam CW, Mangiacapra F, Entjes R, Chung IS, Sels JW, Tonino PA, De Bruyne B, Pijls NH, Fearon WF; FAME Study Investigators. Functional SYNTAX score for risk assessment in multivessel coronary artery disease. *J Am Coll Cardiol*. 2011;58:1211-8.
13. Serruys PW, Farooq V, Vranckx P, Girasis C, Brugaletta S, Garcia-Garcia HM, Holmes DR, Kappetein AP, Mack MJ, Feldman T, Morice MC, Stähle E, James S, Colombo A, Pereda P, Huang J, Morel MA, Van Es GA, Dawkins KD, Mohr FW, Steyerberg EW. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. *JACC Cardiovasc Interv*. 2012;5:606-17.
14. Farooq V, Vergouwe Y, Raber L, Vranckx P, Garcia-Garcia H, Diletti R, Kappetein AP, Morel MA, de Vries T, Swart M, Valgimigli M, Dawkins KD, Windecker S, Steyerberg EW, Serruys PW. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. *Eur Heart J*. 2012;33:3098-104.
15. Iqbal J, Vergouwe Y, Bourantas CV, van Klaveren D, Zhang YJ, Campos CM, Garcia-Garcia HM, Morel MA, Valgimigli M, Windecker S, Steyerberg EW, Serruys PW. Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. *JACC Cardiovasc Interv*. 2014;7:464-70.
16. Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Asano T, Katagiri Y, van Geuns RM, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek JJ, Spitzer E, Juni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Serruys PW. Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. *EuroIntervention*. 2019;15:e539-46.
17. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice MC, Stähle E, Onuma Y, Morel MA, Garcia-Garcia HM, van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. *Lancet*. 2013;381:639-50.
18. Collet C, Onuma Y, Andreini D, Sonck J, Pompilio G, Mushtaq S, La Meir M, Miyazaki Y, de Mey J, Gaemperli O, Ouda A, Maureira JP, Mandry D, Camenzind E, Macron L, Doenst T, Teichgräber U, Sigusch H, Asano T, Katagiri Y, Morel MA, Lindeboom W, Pontone G, Lüscher TF, Bartorelli AL, Serruys PW. Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease. *Eur Heart J*. 2018;39:3689-98.
19. Kobayashi Y, Lonborg J, Jong A, Nishi T, De Bruyne B, Hofsten DE, Kelbaek H, Layland J, Nam CW, Pijls NHJ, Tonino PAL, Warnoe J, Oldroyd KG, Berry C, Engstrom T, Fearon WF; DANAMI-3-PRIMULTI, FAME, and FAMOUS-NSTEMI Study Investigators. Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS. *J Am Coll Cardiol*. 2018;72:1321-9.
20. Farooq V, Serruys PW, Chichareon P. Risk stratification and risk scores. In: Camm AJ, Lüscher TF, Maurer G, Serruys PW, eds. *The ESC Textbook of Cardiovascular Medicine*, third edition. Oxford, UK: Oxford University Press; 2019.
21. Brener SJ, Leon MB, Serruys PW, Smits PC, von Birgelen C, Mehran R, Kirtane AJ, Witzensbichler B, Rinaldi MJ, Metzger DC, Mazzaferri EL, Zhang Z, Stone GW; Collaborators. Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention. *EuroIntervention*. 2019;15:e551-7.
22. Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet*. 2017;389:1025-34.
23. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzensbichler B, Weisz G, Steg PG, Pocock S. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. *J Am Coll Cardiol*. 2016;67:2224-34.
24. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. *JAMA*. 2016;315:1735-49.
25. Serruys PW, Modolo R, Reardon MJ, Miyazaki Y, Windecker S, Popma JJ, Chang Y, Kleiman NS, Lilly SM, Amrane H, Boonstra PW, Kappetein AP, Onuma Y, Sondergaard L, Van Mieghem NM. One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. *EuroIntervention*. 2018;14:877-83.
26. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. 2010;363:1597-607.
27. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG; PARTNER 2 Investigators. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med*. 2016;374:1609-20.
28. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med*. 2019;380:1695-705.

29. Sotomi Y, Onuma Y, Cavalcante R, Ahn JM, Lee CW, van Klaveren D, de Winter RJ, Wykrzykowska JJ, Farooq V, Morice MC, Steyerberg EW, Park SJ, Serruys PW. Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease: A Meta-Analysis From SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery), PRECOMBAT (Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease), and BEST (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease) Randomized Controlled Trials. *Circ Cardiovasc Interv.* 2017 May;10(5).
30. Jaski BE, Serruys PW. Epicardial wall motion and left ventricular function during coronary graft angioplasty in humans. *J Am Coll Cardiol.* 1985;6:695-700.
31. Serruys PW, Brower RW, ten Katen HJ, Meester GT. Recovery from circulatory depression after coronary artery bypass surgery. *Eur Surg Res.* 1980;12:369-82.
32. Brower R, Serruys P, Bos E, Nauta J. Regional myocardial shortening in relation to graft-reactive hyperemia and flow after coronary bypass surgery. *J Thorac Cardiovasc Surg.* 1979;77:92-100.
33. Serruys PW, Hugenholtz PG, Brower RW. [Regional myocardial shortening and blood flow through the graft after aorto-coronary bypass surgery]. [Article in French]. *Arch Mal Coeur Vaiss.* 1979;72:221-30.
34. Serruys PW, Juillière Y, Zijlstra F, Beatt KJ, De Feyter PJ, Suryapranata H, Van Den Brand M, Roelandt J. Coronary blood flow velocity during percutaneous transluminal coronary angioplasty as a guide for assessment of the functional result. *Am J Cardiol.* 1988;61:253-9.
35. Gould KL. Pressure-flow characteristics of coronary stenoses in unsedated dogs at rest and during coronary vasodilation. *Circ Res.* 1978;43:242-53.
36. Serruys PW, Di Mario C, Meneveau N, de Jaegere P, Strikwerda S, de Feyter PJ, Emanuelsson H. Intracoronary pressure and flow velocity with sensor-tip guidewires: a new methodologic approach for assessment of coronary hemodynamics before and after coronary interventions. *Am J Cardiol.* 1993;71:41d-53d.
37. Di Mario C, Krams R, Gil R, Serruys PW. Slope of the instantaneous hyperemic diastolic coronary flow velocity-pressure relation. A new index for assessment of the physiological significance of coronary stenosis in humans. *Circulation.* 1994;90:1215-24.
38. Lamm C, Dohnal M, Serruys PW, Emanuelsson H. High-fidelity translational pressure gradients during percutaneous transluminal coronary angioplasty: correlation with quantitative coronary angiography. *Am Heart J.* 1993;126:66-75.
39. Serruys PW, di Mario C, Piek J, Schroeder E, Vrints C, Probst P, de Bruyne B, Hanet C, Fleck E, Haude M, Verna E, Voudris V, Geschwind H, Emanuelsson H, Muhlberger V, Danzi G, Peels HO, Ford AJ Jr, Boersma E. Prognostic value of intracoronary flow velocity and diameter stenosis in assessing the short- and long-term outcomes of coronary balloon angioplasty: the DEBATE Study (Doppler Endpoints Balloon Angioplasty Trial Europe). *Circulation.* 1997;96:3369-77.
40. Di Mario C, Moses JW, Anderson TJ, Bonan R, Muramatsu T, Jain AC, Suarez de Lezo J, Cho SY, Kern M, Meredith IT, Cohen D, Moussa I, Colombo A. Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint STenting International Investigation). *Circulation.* 2000;102:2938-44.
41. Leaman DM, Brower RW, Meester GT, Serruys P, van den Brand M. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. *Circulation.* 1981;63:285-99.
42. Mushtaq S, De Araujo Goncalves P, Garcia-Garcia HM, Pontone G, Bartorelli AL, Bertella E, Campos CM, Pepi M, Serruys PW, Andreini D. Long-term prognostic effect of coronary atherosclerotic burden: validation of the computed tomography-Leaman score. *Circ Cardiovasc Imaging.* 2015;8:e002332.
43. Meier B. His master's art, Andreas Grüntzig's approach to performing and teaching coronary angioplasty. *EuroIntervention.* 2017;13:15-27.
44. Reiber JH, Serruys PW, Kooijman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schuurbiens JC, den Boer A, Hugenholtz PG. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. *Circulation.* 1985;71:280-8.
45. Wijns W, Serruys PW, Reiber JH, van den Brand M, Simoons ML, Kooijman CJ, Balakumaran K, Hugenholtz PG. Quantitative angiography of the left anterior descending coronary artery: correlations with pressure gradient and results of exercise thallium scintigraphy. *Circulation.* 1985;71:273-9.
46. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *N Engl J Med.* 1996;334:1703-8.
47. Puel J, Juillière Y, Bertrand ME, Rickards AF, Sigwart U, Serruys PW. Early and late assessment of stenosis geometry after coronary arterial stenting. *Am J Cardiol.* 1988;61:546-53.
48. Young DF, Cholvin NR, Roth AC. Pressure drop across artificially induced stenoses in the femoral arteries of dogs. *Circ Res.* 1975;36:735-43.
49. Kirkeeide RL, Gould KL. Cardiovascular imaging: coronary artery stenosis. *Hosp Pract (Off Ed).* 1984;19:160-3.
50. Emanuelsson H, Dohnal M, Lamm C, Tenerz L. Initial experiences with a miniaturized pressure transducer during coronary angioplasty. *Catheter Cardiovasc Diagn.* 1991;24:1343.
51. Echavarría-Pinto M, Collet C, Escaned J, Piek JJ, Serruys PW. State of the art: pressure wire and coronary functional assessment. *EuroIntervention.* 2017;13:666-79.
52. Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. *Circulation.* 1993;87:1354-67.
53. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bar F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol.* 2007;49:2105-11.
54. Tonino PA, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engström T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med.* 2009;360:213-24.
55. De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med.* 2012;367:991-1001.
56. Serruys PW, de Jaegere P, Kiemeneijf F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med.* 1994;331:489-95.
57. Collet C, Onuma Y, Sonck J, Asano T, Vandelooy B, Kornowski R, Tu S, Westra J, Holm NR, Xu B, de Winter RJ, Tijssen JG, Miyazaki Y, Katagiri Y, Tenekecioglu E, Modolo R, Chichareon P, Cosyns B, Schoors D, Roosens B, Lochy S, Argacha JF, van Rosendael A, Bax J, Reiber JHC, Escaned J, De Bruyne B, Wijns W, Serruys PW. Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. *Eur Heart J.* 2018;39:3314-21.
58. Asano T, Katagiri Y, Chang CC, Kogame N, Chichareon P, Takahashi K, Modolo R, Tenekecioglu E, Collet C, Jonker H, Appleby C, Zaman A, van

- Mieghem N, Uren N, Zueco J, Piek JJ, Reiber JHC, Farooq V, Escaned J, Banning AP, Serruys PW, Onuma Y. Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial: Feasibility, Diagnostic Performance of Quantitative Flow Ratio, and Clinical Prognostic Value of Functional SYNTAX Score Derived From Quantitative Flow Ratio in Patients With 3-Vessel Disease. *JACC Cardiovasc Interv.* 2019;12:259-70.
59. Papafaklis MI, Muramatsu T, Ishibashi Y, Lakkas LS, Nakatani S, Bourantas CV, Ligthart J, Onuma Y, Echavarría-Pinto M, Tsirka G, Kotsia A, Nikas DN, Mogabgab O, van Geuns RJ, Naka KK, Fotiadis DI, Brilakis ES, García-García HM, Escaned J, Zijlstra F, Michalis LK, Serruys PW. Fast virtual functional assessment of intermediate coronary lesions using routine angiographic data and blood flow simulation in humans: comparison with pressure wire - fractional flow reserve. *EuroIntervention.* 2014;10:574-83.
60. Sen S, Escaned J, Malik IS, Mikhail GW, Foale RA, Mila R, Tarkin J, Petraco R, Broyd C, Jabbour R, Sethi A, Baker CS, Bellamy M, Al-Bustami M, Hackett D, Khan M, Lefroy D, Parker KH, Hughes AD, Francis DP, Di Mario C, Mayet J, Davies JE. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. *J Am Coll Cardiol.* 2012;59:1392-402.
61. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbada RK, Patel MR, Serruys P, Escaned J. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. *N Engl J Med.* 2017;376:1824-34.
62. Götzberg M, Christiansen EH, Gudmundsdóttir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson SE, Öhagen P, Olsson H, Omerovic E, Calais F, Lindroos P, Maeng M, Tödt T, Venetsanos D, James SK, Käregren A, Nilsson M, Carlsson J, Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Fröbert O; iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. *N Engl J Med.* 2017;376:1813-23.
63. Krams R, Wentzel JJ, Oomen JA, Vinke R, Schuurbiens JC, de Feyter PJ, Serruys PW, Slager CJ. Evaluation of endothelial shear stress and 3D geometry as factors determining the development of atherosclerosis and remodeling in human coronary arteries in vivo. Combining 3D reconstruction from angiography and IVUS (ANGUS) with computational fluid dynamics. *Arterioscler Thromb Vasc Biol.* 1997;17:2061-5.
64. Łukaszewicz G, Kalita P. Navier–Stokes Equations: An Introduction with Applications. Cham, Switzerland: Springer International Publishing; 2016.
65. Serruys PW, Girasis C, Papadopoulou SL, Onuma Y. Non-invasive fractional flow reserve: scientific basis, methods and perspectives. *EuroIntervention.* 2012;8:511-9.
66. Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. *JACC Cardiovasc Interv.* 2016;9:2024-35.
67. Tu S, Barbato E, Kőszegi Z, Yang J, Sun Z, Holm NR, Tar B, Li Y, Rusinaru D, Wijns W, Reiber JH. Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries. *JACC Cardiovasc Interv.* 2014;7:768-77.
68. HeartFlow FFR_{CT} for estimating fractional flow reserve from coronary CT angiography. Medical technologies guidance [MTG32], 2017. <https://www.nice.org.uk/guidance/mtg32> (last accessed 22 July 2019).
69. Echavarría-Pinto M, Escaned J, Macías E, Medina M, Gonzalo N, Petraco R, Sen S, Jimenez-Quevedo P, Hernandez R, Mila R, Ibanez B, Nunez-Gil IJ, Fernandez C, Alfonso F, Banuelos C, Garcia E, Davies J, Fernandez-Ortiz A, Macaya C. Disturbed coronary hemodynamics in vessels with intermediate stenoses evaluated with fractional flow reserve: a combined analysis of epicardial and microcirculatory involvement in ischemic heart disease. *Circulation.* 2013;128:2557-66.
70. Vogel R, LeFree M, Bates E, O'Neill W, Foster R, Kirilin P, Smith D, Pitt B. Application of digital techniques to selective coronary arteriography: use of myocardial contrast appearance time to measure coronary flow reserve. *Am Heart J.* 1984;107:153-64.
71. Suryapranata H, Zijlstra F, MacLeod DC, van den Brand M, de Feyter PJ, Serruys PW. Predictive value of reactive hyperemic response on reperfusion on recovery of regional myocardial function after coronary angioplasty in acute myocardial infarction. *Circulation.* 1994;89:1109-17.
72. Modolo R, Collet C, Onuma Y, Serruys PW. SYNTAX II and SYNTAX III trials: what is the take home message for surgeons? *Ann Cardiothorac Surg.* 2018;7:470-82.
73. Klocke FJ. Measurements of coronary flow reserve: defining pathophysiology versus making decisions about patient care. *Circulation.* 1987;76:1183-9.
74. Echavarría-Pinto M, van de Hoef T, García García HM, Cerrato E, Broyd C, Serruys P, Piek JJ, Escaned J. Combined use of intracoronary pressure and flow to assess ischemic heart disease. In: Escaned J, Serruys P, eds. Coronary stenosis imaging, structure and physiology. Second edition. Toulouse, France: Europa Digital & Publishing; 2015.
75. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med.* 2009;360:961-72.
76. Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein AP, Van Dyck N, Mack M, Holmes D, Feldman T, Morice MC, Colombo A, Bass E, Leadley K, Dawkins KD, van Es GA, Morel MA, Mohr FW. Assessment of the SYNTAX score in the Syntax study. *EuroIntervention.* 2009;5:50-6.
77. Escaned J, Collet C, Ryan N, De Maria GL, Walsh S, Sabate M, Davies J, Lesiak M, Moreno R, Cruz-Gonzalez I, Hoole SP, Ej West N, Piek JJ, Zaman A, Fath-Ordoubadi F, Stables RH, Appleby C, van Mieghem N, van Geuns RJ, Uren N, Zueco J, Buszman P, Iniguez A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, Hanratty C, Cavalcante R, Kappetein AP, Taggart DP, van Es GA, Morel MA, de Vries T, Onuma Y, Farooq V, Serruys PW, Banning AP. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. *Eur Heart J.* 2017;38:3124-34.
78. Sonck J, Miyazaki Y, Collet C, Onuma Y, Asano T, Takahashi K, Kogame N, Katagiri Y, Modolo R, Serruys PW, Bartorelli AL, Andreini D, Doenst T, Maureira JP, Plass A, La Meir M, Pompillio G. Feasibility of planning coronary artery bypass grafting based only on coronary computed tomography angiography and CT-derived fractional flow reserve: a pilot survey of the surgeons involved in the randomized SYNTAX III Revolution trial. *Interact Cardiovasc Thorac Surg.* 2019 Mar 18. [Epub ahead of print].